Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2020 Jan 29

PMID 31988977

Citations 2

Authors

Elia Lo Priore

David M Livermore

Niccolo Buetti

Philipp Jent

Niklas Pelzer

Carlo Casanova

Hansjakob Furrer

Baharak Babouee Flury

Affiliations

Soon will be listed here.

Abstract

We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ESBL.

Citing Articles

Carbapenem-resistant Citrobacter amalonaticus and VRE bacteraemia in an immunocompetent patient after a urological Rezum procedure.

Midlick D, Harhay J, Summers N Access Microbiol. 2024; 6(10).

PMID: 39391376 PMC: 11465632. DOI: 10.1099/acmi.0.000852.v4.

Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports.

Charles R, Adhikari S, Mittal A, Chaudhuri S, Gupta M, Khot W Infez Med. 2022; 30(4):516-524.

PMID: 36482959 PMC: 9715003. DOI: 10.53854/liim-3004-5.

References

Perilli M, Mancini A, Celenza G, Bottoni C, Bellio P, Sabatini A . Kinetic study of the effect of histidines 240 and 164 on TEM-149 enzyme probed by β-lactam inhibitors. Antimicrob Agents Chemother. 2014; 58(10):6294-6. PMC: 4187899. DOI: 10.1128/AAC.02950-14. View

Lauf L, Ozsvar Z, Mitha I, Regoly-Merei J, Embil J, Cooper A . Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014; 78(4):469-80. DOI: 10.1016/j.diagmicrobio.2013.12.007. View

Ellis-Grosse E, Babinchak T, Dartois N, Rose G, Loh E . The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005; 41 Suppl 5:S341-53. DOI: 10.1086/431675. View

Bergallo C, Jasovich A, Teglia O, Oliva M, Lentnek A, de Wouters L . Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2008; 63(1):52-61. DOI: 10.1016/j.diagmicrobio.2008.09.001. View

Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K . Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol. 1998; 5(3):243-6. DOI: 10.1111/j.1442-2042.1998.tb00597.x. View

Meagher A, Ambrose P, Grasela T, Ellis-Grosse E . The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005; 41 Suppl 5:S333-40. DOI: 10.1086/431674. View

Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N . Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003; 49(6):269-79. DOI: 10.1159/000074526. View

Freire A, Melnyk V, Kim M, Datsenko O, Dzyublik O, Glumcher F . Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010; 68(2):140-51. DOI: 10.1016/j.diagmicrobio.2010.05.012. View

Babinchak T, Ellis-Grosse E, Dartois N, Rose G, Loh E . The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41 Suppl 5:S354-67. DOI: 10.1086/431676. View

10.

Doi Y . Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis. 2019; 69(Suppl 7):S565-S575. PMC: 6853760. DOI: 10.1093/cid/ciz830. View

11.

Bates D, Parkins M, Hellweg R, Gibson K, Bugar J . Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review. Can J Hosp Pharm. 2012; 65(3):209-15. PMC: 3379828. DOI: 10.4212/cjhp.v65i3.1144. View

12.

Geerlings S, van Donselaar-van der Pant K, Keur I . Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2010; 65(9):2048-9. DOI: 10.1093/jac/dkq224. View

13.

Pogue J, Lee J, Marchaim D, Yee V, Zhao J, Chopra T . Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011; 53(9):879-84. DOI: 10.1093/cid/cir611. View

14.

Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P . Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019; 90(4):227-248. DOI: 10.4081/aiua.2018.4.227. View

15.

Drekonja D, Johnson J . Tigecycline treatment for urinary tract infections: case report and literature review. J Chemother. 2011; 23(3):168-70. DOI: 10.1179/joc.2011.23.3.168. View